查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840759

C反應蛋白檢測市場按產品類型、技術、最終用戶、應用、檢測類型和樣品類型分類－2025-2032年全球預測

C-Reactive Protein Testing Market by Product, Technology, End User, Application, Test Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，C 反應蛋白檢測市場將成長至 44.3 億美元，複合年成長率為 12.77%。

關鍵市場統計數據
基準年 2024 16.9億美元
預計年份：2025年 19.1億美元
預測年份 2032 44.3億美元
複合年成長率 (%) 12.77%

了解C反應蛋白檢測在急診、慢性病管理和人群健康管理的臨床重要性和不斷發展的效用

C反應蛋白（CRP）檢測處於臨床診斷和人群健康管理的關鍵交匯點，它既是全身發炎的快速生化指標，也是整體急性和慢性疾病的替代標記。在臨床實踐中，CRP檢測結果可用於指導感染疾病和發炎性疾病的診斷路徑，指南自體免疫疾病的治療監測，並在採用高敏感性CRP（hs-CRP）檢測方法時用於心血管風險分層。檢測方式從集中式平台向分散式即時檢測（POC​​）解決方案的演變，擴大了臨床應用範圍，並拓展了CRP結果影響決策的適用場景。

技術進步和醫療模式的變革正在顯著改變臨床醫生對檢測週轉時間、分析靈敏度以及與醫療資訊系統無縫整合等方面的期望。因此，採購團隊和實驗室管理人員在評估CRP檢測時，不僅要考慮其分析性能，還要考慮其與工作流程的兼容性、總體擁有成本以及與電子健康記錄和實驗室資訊系統的互通性。隨著CRP臨床應用範圍的擴大，醫院、門診和研究機構的相關人員正在重新調整如何將CRP資料納入診斷演算法和慢性病管理路徑。

快速分散化、檢測靈敏度提高和資訊服務整合如何重新定義CRP診斷在臨床護理中的策略價值

由於技術創新、臨床指南的不斷更新以及診斷的去中心化，CRP檢測領域正在發生顯著變化。即時檢測（POC​​）分析儀正從基本的定性輸出轉向快速提供定量、具有臨床意義的CRP值，從而支持在門診和急診環境中進行現場臨床決策。同時，實驗室分析儀的通量和自動化程度也不斷提高，試劑開發人員也在改進檢測化學方法，以提高高敏感性CRP（hs-CRP）應用（尤其是與心血管風險評估相關的應用）的靈敏度和特異性。

隨著相關人員要求標準化報告、統一的品管以及將CRP結果整合到更廣泛的臨床決策支援工具中，資料管理和諮詢服務的重要性日益凸顯。此外，將發炎標記與代謝、腫瘤和感染疾病病理聯繫起來的多學科研究，正在創造超越傳統急診診斷的全新臨床應用場景。簡而言之，市場正從將CRP檢測視為商品的觀念轉向以價值主導的模式，在這種模式下，分析性能、工作流程整合和實際應用價值決定了檢測的普及程度。

評估2025年美國關稅對CRP測試採購和製造策略的累積營運和供應鏈影響

近期美國針對進口商品實施的關稅措施（有效期至2025年）造成了複雜的貿易影響，波及CRP檢測組件和成品設備的供應鏈及籌資策略。依賴跨境採購儀器、試劑或關鍵耗材的製造商正面臨到岸成本變化和前置作業時間延長的困境，促使許多製造商重新評估其供應鏈彈性措施。為此，一些上游供應商正在加速推進雙通路採購策略並增加庫存緩衝以緩解供應中斷，而下游實驗室客戶則在調整採購計畫以保障臨床工作的連續性。

關稅調整不僅影響直接的成本和物流，也影響更長期的策略決策，例如最佳化區域製造地和試劑在地化生產，以降低貿易波動帶來的風險。這種轉變也促使診斷試劑生產商與契約製造鏈的靈活性和供應商的透明度已成為依賴CRP檢測的機構的首要考慮因素。

透過對產品、技術、最終用戶、應用、檢測類型和樣本類型進行全面的細分分析，揭示了CRP檢測的臨床重點和創新路徑。

精細化的細分視角揭示了影響產品、技術、最終用戶、應用、測試類型和樣本類型採購和開發優先順序的差異化需求促進因素和營運標準。在產品方面，相關人員對分析儀類別中的實驗室分析儀和照護現場儀的評估期望各不相同。實驗室分析儀優先考慮通量和自動化，而照護現場分析儀則強調速度、便攜性和易用性。試劑和套件分為 CRP套件和 hs-CRP套件，檢測敏感度和批間一致性會影響臨床效用。軟體和服務包括支援品質保證、互通性和縱向資料分析的諮詢和資料管理軟體。

技術選擇——包括酶聯免疫吸附試驗 (ELISA)、免疫比濁法（包括乳膠增強法和濁度法）以及濁度法——會影響測量精度、試樣處理通量以及與現有設備的兼容性。最終用戶的需求各不相同。學術研究中心優先考慮檢測方法的靈活性和新型標記的驗證，而臨床機構（包括一級和二級醫療機構）則優先考慮快速週轉和易於操作。診斷和監測應用十分廣泛，包括心血管疾病（臨床醫生需要區分心臟疾病和卒中風險）、糖尿病篩檢以及各種感染疾病和發炎性疾病，包括自體免疫疾病以及細菌和病毒感染。檢測類型的選擇區分了半定量方法（例如免疫電泳和側向層析檢測）和具有自動化或手動檢測流程的定量方法，每種方法都會影響臨床解讀和照護現場的適用性。最後，血漿、血清、全血以及EDTA血漿與肝素血漿、毛細血管全血與靜脈全血等亞類樣本類型的選擇，將決定門診或現場環境下的分析前工作流程和可及性。總而言之，這些細分視角有助於明確在哪些方面進行漸進式創新、有針對性的商業化和營運投資能夠帶來最大的臨床和商業性效益。

主要全球區域的基礎設施、監管差異和醫療服務模式將如何決定CRP檢測的普及路徑和供應策略？

區域動態將對美洲、歐洲、中東和非洲以及亞太地區的CRP檢測應用模式、供應鏈規劃、監管合規以及臨床偏好產生重大影響。在美洲，整合的醫療保健系統和完善的實驗室基礎設施（支援集中式高通量檢測和即時檢測服務）正在推動臨床應用。在歐洲、中東和非洲，利害關係人面臨管理體制和基礎設施差異所帶來的挑戰。在許多市場，統一的標準與強大的集中式實驗室網路並存，同時，尤其是在城市中心，相關人員對分散式診斷的需求也不斷成長。

亞太地區擁有強大的大規模生產能力、都市區醫療中心快速的技術應用能力，以及從大型醫院系統到社區診所等多元化的終端使用者群體。這些地區為尋求最佳化分銷、本地化生產和監管策略的製造商和服務供應商帶來了獨特的挑戰和機會。因此，為確保CRP檢測解決方案的持續應用，策略性進入和擴張計畫必須與各地區的臨床實踐模式、採購方式以及實驗室網路的成熟度相符。

繪製競爭生態系圖，展現儀器製造商、試劑專家、軟體供應商和即時檢測創新者如何齊聚一堂，共同定義 CRP 診斷的價值。

CRP檢測生態系統的競爭格局呈現出多元化的特點，既有成熟的診斷試劑製造商，也有專業的試劑開發商、軟體和資訊服務提供商，以及敏捷的即時檢測（POC​​）創新者，所有這些參與者都在影響著產品的可及性、性能基準化分析和服務模式。領先的儀器製造商正在擴展平台互通性，以適應更廣泛的檢測化學方法，而試劑專家則致力於提高檢測穩定性並降低分析前變異性。同時，軟體供應商和顧問公司正在增強資料管理能力，以提供自動化品管、趨勢分析以及與電子健康記錄的整合。

儀器製造商與第三方試劑供應商之間的夥伴關係仍然普遍，而與契約製造製造商的策略聯盟也在不斷增加，以支持靈活的生產和本地化供應。新參與企業正透過即時檢測外形規格、簡化的非實驗室負責人操作流程以及包含遠端連接和效能監控的配套服務來脫穎而出。對於採購人員和決策者而言，選擇供應商越來越依賴臨床效能、法規遵循、售後支援以及提供端到端解決方案的能力，從而降低實施風險和營運複雜性。

診斷試劑生產商和醫療保健提供者可採取的切實可行的策略重點，以加快 CRP 檢測的效能、普及性和供應彈性。

尋求鞏固市場地位和提升臨床影響力的產業領導者應優先考慮平衡創新、供應鏈韌性和互通性的工作。首先，投資提高高敏C反應蛋白（hs-CRP）的敏感性和可重複性，尤其能夠滿足心血管風險評估和發炎性疾病監測方面尚未滿足的臨床需求。其次，擴展可與實驗室資訊系統整合的模組化照護現場平台，將有助於在門診和急診環境中更廣泛地應用，從而在就診時即可進行臨床決策並最佳化診療路徑。

此外，企業應透過發展區域製造能力或與國內委託製造製造商合作來實現供應鏈多元化，從而降低貿易波動帶來的風險。與臨床網路和研究機構建立策略聯盟可以加速真實世界證據的生成，並支持指南的發展。最後，將強大的資料管理、遠端監測和上市後監控服務整合到產品中，可以為客戶提供可衡量的品質保證和長期價值，從而增強商業性差異化和客戶維繫。

一種透明的、多來源的調查方法，結合了相關人員訪談、臨床檢驗證據和技術性能評估，能夠提供可操作的見解。

本執行摘要的研究基礎包括對主要相關人員、採購負責人、醫院臨床醫生、照護現場專案經理和檢測方法開發科學家進行討論，以了解實際運作中的限制因素和臨床決策促進因素。二級資訊來源包括方法學綜述和檢測方法驗證研究，以評估酵素連結免疫吸附試驗 (ELISA)、免疫比濁法和濁度法等分析方法之間的權衡取捨。

資料整合優先考慮方法學的透明度，並著重於檢測驗證參數、重複性指標和樣本類型可比較性。品質保證評估檢視了監管許可、批間一致性記錄以及上市後績效報告（如有）。分析框架將定性見解與技術性能特徵相結合，從而為產品開發、採購和臨床實施策略提供切實可行的建議。在整個過程中，我們始終關注分析前變數和工作流程整合，因為我們認知到它們對臨床效用和操作推廣有顯著影響。

最後總結如何透過調整檢測效能、工作流程整合和供應靈活性，最大限度地提高 CRP 檢測的臨床和營運價值。

總之，C反應蛋白檢測在急診、慢性病管理和研究中具有重要的臨床意義，隨著診斷模式向快速、分散和數據整合的醫療模式轉變，其策略重要性日益凸顯。儀器性能、檢測化學、資訊服務和法規環境之間的相互作用將決定CRP檢測在不同醫療機構中的普及速度和有效性。由於供應鏈因素和貿易措施會影響採購動態，各機構必須優先考慮靈活性、供應商透明度和本地化供應方案，以維持臨床服務的連續性。

展望未來，最具影響力的機會將出現在分析績效提升、工作流程無縫整合以及臨床療效顯著結合的領域。因此，決策者應將投資與能夠帶來明確臨床價值的應用情境結合，確保與醫療資訊系統的互通性，並優先考慮能夠加速真實世界證據產生的合作。如此一來，相關人員便可將CRP檢測不僅作為一種檢測手段，更作為一種策略性診斷工具，從而支持更佳的病患管理和系統層面的效率提升。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 照護現場CRP檢測平台技術的進步使得快速床邊發炎監測成為可能。
  • 高敏C反應蛋白的監管核准和標準化工作
  • 將CRP檢測與數位健康工具結合，用於個人化心血管風險評估
  • 病患自我護理趨勢推動了家用C反應蛋白監測套件的廣泛應用。
  • 新興的多重免疫檢測結合了CRP和細胞激素譜，用於全面的發炎分析。
  • 診斷公司與Start-Ups建立策略夥伴關係，共同創新CRP檢測技術
  • 隨著慢性發炎性疾病盛行率的上升，新興市場對CRP檢測的應用也日益增加。
  • 遠端醫療擴展對遠距CRP樣本採集和虛擬診斷工作流程的影響
  • 微流體和實驗室晶片CRP檢測系統的進步縮短了檢測時間和樣本用量。
  • 擴大醫療支付方對高靈敏度CRP檢測的報銷和政策支持

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. C反應蛋白檢測市場（依產品類型分類）

  • 裝置
    • 實驗室分析設備
    • 照護現場分析儀
  • 試劑和套件
    • CRP套件
    • 高敏C反應蛋白試劑套件
  • 軟體和服務
    • 諮詢服務
    • 資料管理軟體

9. C反應蛋白檢測市場（依技術分類）

  • 伊麗莎
  • 免疫比濁法
    • 乳膠加固
    • 濁度計
  • 濁度法

10. C反應蛋白檢測市場（依最終用戶分類）

  • 學術研究機構
  • 診所
    • 一級診所
    • 二級診所
  • 診斷實驗室
    • 醫院實驗室
    • 獨立實驗室
  • 醫院
    • 綜合醫院
    • 專科醫院

第11章 C反應蛋白檢測市場（依應用領域分類）

  • 癌症
  • 心血管疾病
    • 冠狀動脈疾病
    • 中風
  • 糖尿病
  • 感染疾病和發炎性疾病
    • 自體免疫疾病
    • 細菌感染疾病
    • 病毒感染

12. C反應蛋白檢測市場（依檢測類型分類）

  • 定量
    • 自動化測試
    • 手動測試
  • 半定量
    • 免疫泳
    • 側向流動試驗

13. C反應蛋白檢測市場（依樣本類型分類）

  • 電漿
    • EDTA血漿
    • 肝素血漿
  • 血清
  • 全血
    • 微血管血
    • 靜脈血

14. C反應蛋白檢測市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 C反應蛋白檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國 C 反應蛋白檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Diagnostics International AG
    • Abbott Laboratories, Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Ortho Clinical Diagnostics, LLC
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd
Product Code: MRR-A339DAEFABD5

The C-Reactive Protein Testing Market is projected to grow by USD 4.43 billion at a CAGR of 12.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.91 billion
Forecast Year [2032] USD 4.43 billion
CAGR (%) 12.77%

Understanding the clinical centrality and evolving utility of C-reactive protein testing across acute care, chronic disease management, and population health settings

C-reactive protein (CRP) testing occupies a vital intersection between clinical diagnostics and population health management, serving as a rapid biochemical indicator of systemic inflammation and a surrogate marker across a spectrum of acute and chronic conditions. In clinical practice, CRP assays inform diagnostic pathways for infection and inflammatory disorders, guide therapeutic monitoring in autoimmune disease, and contribute to cardiovascular risk stratification when high-sensitivity (hs-CRP) methods are employed. The evolution of testing modalities from centralized laboratory platforms to decentralized point-of-care solutions has expanded both clinical access and the contexts in which CRP results influence decision-making.

Technological advancement and shifting care models are reshaping clinician expectations about turnaround time, analytical sensitivity, and seamless integration with health information systems. Consequently, procurement teams and laboratory managers must evaluate CRP testing not solely on analytical performance but also on workflow compatibility, total cost of ownership, and interoperability with electronic medical records and laboratory information systems. As the clinical applications of CRP broaden, stakeholders across hospitals, outpatient clinics, and research environments are recalibrating how they incorporate CRP data into diagnostic algorithms and chronic disease management pathways.

How rapid decentralization, assay sensitivity improvements, and integrated data services are redefining the strategic value of CRP diagnostics in clinical care

The landscape for CRP testing is undergoing transformative shifts driven by technological innovation, evolving clinical guidelines, and the decentralization of diagnostics. Point-of-care analyzers are moving beyond basic qualitative outputs to provide quantitative, clinically actionable CRP values with rapid turnaround, enabling same-visit clinical decisions in both outpatient and emergency settings. Simultaneously, laboratory analyzers are increasing throughput and automation while reagent developers refine assay chemistries to enhance sensitivity and specificity, especially for hs-CRP applications relevant to cardiovascular risk assessment.

Data management and consulting services are growing in importance as stakeholders demand standardized reporting, quality control harmonization, and integration of CRP results into broader clinical decision support tools. Moreover, cross-disciplinary research linking inflammation markers to metabolic, oncologic, and infectious disease pathways is fueling novel clinical use cases that extend beyond traditional acute care diagnostics. In short, the market is shifting from a commodity perception of CRP assays to a value-driven model where analytical performance, workflow integration, and real-world clinical impact determine adoption.

Assessing the cumulative operational and supply chain consequences of 2025 US tariff measures on CRP testing procurement and manufacturing strategies

Recent tariff actions affecting imports into the United States in 2025 have created a complex overlay of trade-related considerations that influence supply chains and procurement strategies for CRP testing components and finished devices. Manufacturers that rely on cross-border sourcing for instruments, assay reagents, or critical consumables have encountered altered landed costs and extended lead times, prompting many to re-evaluate supply resiliency measures. In response, several upstream suppliers have accelerated dual-sourcing strategies and increased inventory buffers to mitigate disruption, with downstream laboratory customers adjusting procurement cadence to protect clinical continuity.

Beyond immediate cost and logistics effects, tariff-induced adjustments have influenced longer-term strategic decisions, including regional manufacturing footprint optimization and localized reagent production to reduce exposure to trade fluctuations. This shift has also heightened collaboration between diagnostic firms and contract manufacturers that possess domestic capabilities, thereby shortening supply chains and enhancing quality oversight. In parallel, purchasing groups and health systems are pursuing consolidated contracting models to secure more predictable terms and to leverage volume for better pricing stability. Overall, the cumulative impact has been to make supply chain flexibility and supplier transparency top priorities for organizations that rely on CRP testing.

Comprehensive segmentation analysis across product, technology, end user, application, test type, and sample type to illuminate clinical priorities and innovation pathways for CRP testing

A granular segmentation view reveals differentiated demand drivers and operational criteria across product, technology, end user, application, test type, and sample type that shape procurement and development priorities. From a product perspective, stakeholders evaluate laboratory analyzers and point-of-care analyzers under the instruments category with distinct expectations: centralized laboratory analyzers prioritize throughput and automation while point-of-care analyzers emphasize speed, portability, and ease of use. Reagents and kits are divided between CRP kits and hs-CRP kits, where assay sensitivity and lot-to-lot consistency affect clinical utility. Software and services encompass consulting offerings and data management software that support quality assurance, interoperability, and longitudinal data analytics.

Technology choices-whether ELISA, immunoturbidimetric approaches including latex-enhanced or turbidimetric variants, or nephelometry-affect assay precision, sample throughput, and compatibility with existing instrumentation. End-user contexts vary widely: academic and research institutes focus on assay flexibility and novel marker validation while clinics, which include both tier I and tier II facilities, prioritize rapid turnaround and ease of operation; diagnostic laboratories, subdivided into hospital-based and independent labs, balance throughput with assay cost-efficiency; hospitals, whether general or specialized, demand validated workflows and robust quality systems. Applications span diagnostics and monitoring across cancer, cardiovascular disease where clinicians differentiate between coronary heart disease and stroke risk contexts, diabetes screening interactions, and a broad set of infection and inflammatory disorders including autoimmune conditions as well as bacterial and viral infections. Test type considerations distinguish quantitative methods, with automated and manual test pathways, from semi-quantitative approaches such as immunophoresis and lateral flow tests, each informing clinical interpretation and point-of-care suitability. Finally, sample type decisions-between plasma, serum, and whole blood, and their subcategories such as EDTA or heparin plasma and capillary versus venous whole blood-determine pre-analytical workflows and accessibility in ambulatory or field settings. Taken together, these segmentation lenses clarify where incremental innovation, targeted commercialization, and operational investment can yield the greatest clinical and commercial returns.

How regional infrastructure, regulatory diversity, and care delivery models across major global regions determine CRP testing adoption pathways and supply strategies

Regional dynamics exert a profound influence on adoption patterns, supply chain planning, regulatory navigation, and clinical preferences for CRP testing across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical adoption is driven by integrated health systems and widespread laboratory infrastructure that support both centralized high-throughput testing and expansion of point-of-care services; reimbursement frameworks and clinical practice guidelines further shape where hs-CRP assays gain traction. Moving to Europe, Middle East & Africa, stakeholders contend with heterogeneous regulatory regimes and infrastructure variability; in many markets, harmonized standards coexist with pockets of strong centralized laboratory networks and growing demand for decentralized diagnostics, particularly in urban centers.

Asia-Pacific presents a dynamic mix of high-volume manufacturing capability, rapid technology adoption in urban healthcare hubs, and diverse end-user profiles ranging from large hospital systems to community clinics. Collectively, these regions present distinct challenges and opportunities for manufacturers and service providers seeking to optimize distribution, localized manufacturing, and regulatory strategies. Strategic entry or expansion plans should therefore align with each region's clinical practice patterns, procurement norms, and the maturity of laboratory networks to ensure sustainable uptake of CRP testing solutions.

Mapping the competitive ecosystem where instrument makers, reagent specialists, software vendors, and point-of-care innovators converge to define value in CRP diagnostics

Competitive dynamics in the CRP testing ecosystem are characterized by a mix of established diagnostic manufacturers, specialized reagent developers, software and data service providers, and nimble point-of-care innovators that together shape product availability, performance benchmarks, and service models. Leading instrument makers are extending platform interoperability to accommodate a broader range of assay chemistries while reagent specialists focus on improving assay stability and reducing pre-analytical variability. Concurrently, software vendors and consulting firms are enhancing data management capabilities to deliver automated quality control, trend analysis, and integration with electronic health records-functions that increasingly determine the value proposition for clinical laboratories and health systems.

Partnerships between instrumentation companies and third-party reagent suppliers remain common, and strategic alliances with contract manufacturers have increased to support flexible production and regional supply. New entrants are differentiating through point-of-care form factors, simplified workflows for non-laboratory personnel, and bundled service offerings that include remote connectivity and performance monitoring. For purchasers and decision-makers, vendor selection increasingly hinges on demonstrated clinical performance, regulatory compliance, post-market support, and the ability to provide end-to-end solutions that reduce implementation risk and operational complexity.

Actionable strategic priorities for diagnostic manufacturers and healthcare providers to accelerate CRP test performance, adoption, and supply resilience

Industry leaders seeking to strengthen market position and clinical impact should prioritize initiatives that balance innovation, supply resilience, and interoperability. First, investing in assay performance enhancements-particularly for hs-CRP sensitivity and reproducibility-will address unmet clinical needs in cardiovascular risk assessment and inflammatory disease monitoring. Second, expanding modular point-of-care platforms that integrate with laboratory information systems will facilitate broader adoption across outpatient and emergency settings, enabling same-visit clinical decisions and tighter care pathways.

Additionally, companies should diversify supply chains by developing regional manufacturing capabilities or partnering with domestic contract manufacturers to reduce exposure to trade volatility. Strategic collaborations with clinical networks and research institutions can accelerate real-world evidence generation and support guideline inclusion. Finally, embedding robust data management, remote monitoring, and post-market surveillance services into product offerings will provide customers with measurable quality assurance and long-term value, thereby strengthening commercial differentiation and customer retention.

Transparent, multi-source research methodology combining stakeholder interviews, clinical validation evidence, and technology performance assessments to inform actionable insights

The research underpinning this executive summary integrates primary stakeholder interviews, synthesis of peer-reviewed clinical literature, regulatory filings, and a structured assessment of technology performance characteristics. Primary engagement included discussions with clinical laboratory directors, procurement leaders, hospital clinicians, point-of-care program managers, and assay development scientists to capture real-world operational constraints and clinical decision drivers. Secondary sources comprised methodological reviews and assay validation studies to evaluate analytical trade-offs among ELISA, immunoturbidimetric, and nephelometric approaches.

Data synthesis prioritized methodological transparency: inclusion criteria for studies emphasized assay validation parameters, reproducibility metrics, and sample type comparability. Quality assurance assessments evaluated regulatory clearances, documented lot-to-lot consistency, and post-market performance reports when available. The analytical framework triangulated qualitative insights with technical performance characteristics to generate practical recommendations for product development, procurement, and clinical implementation strategies. Throughout, attention was given to pre-analytical variables and workflow integration, recognizing their outsized impact on clinical utility and operational adoption.

Closing synthesis on aligning assay performance, workflow integration, and supply flexibility to maximize clinical and operational value from CRP testing

In conclusion, C-reactive protein testing retains critical clinical relevance across acute care, chronic disease management, and research contexts, and its strategic importance is increasing as diagnostic paradigms shift toward rapid, decentralized, and data-integrated care models. The interplay between instrument capabilities, assay chemistry, data services, and regulatory environments determines how quickly and effectively CRP testing can be adopted in different care settings. As supply chain considerations and trade measures influence procurement dynamics, organizations must emphasize flexibility, vendor transparency, and localized supply options to maintain clinical continuity.

Looking ahead, the most impactful opportunities will arise where analytical performance improvements are coupled with seamless workflow integration and demonstrable clinical outcomes. Decision-makers should therefore align investments with use cases that deliver clear clinical value, ensure interoperability with health information systems, and prioritize collaborations that accelerate real-world evidence generation. By doing so, stakeholders can harness CRP testing not just as a laboratory assay but as a strategic diagnostic tool that supports better patient management and system-level efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in point-of-care CRP testing platforms enabling rapid bedside inflammation monitoring
  • 5.2. Regulatory approvals and standardization efforts for high-sensitivity C-reactive protein assays
  • 5.3. Integration of CRP testing with digital health tools for personalized cardiovascular risk assessment
  • 5.4. Expansion of home-based C-reactive protein monitoring kits driven by patient self-care trends
  • 5.5. Emergence of multiplex immunoassays combining CRP with cytokine panels for comprehensive inflammation profiling
  • 5.6. Strategic collaborations between diagnostics firms and biotech startups to innovate CRP assay technologies
  • 5.7. Growing adoption of CRP testing in emerging markets amid rising prevalence of chronic inflammatory diseases
  • 5.8. Impact of telemedicine expansion on remote CRP sample collection and virtual diagnostic workflows
  • 5.9. Evolution of microfluidic and lab-on-a-chip CRP detection systems reducing assay time and sample volumes
  • 5.10. Increasing reimbursement coverage and policy support for high-sensitivity CRP testing by healthcare payers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. C-Reactive Protein Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Laboratory Analyzers
    • 8.1.2. Point-Of-Care Analyzers
  • 8.2. Reagents & Kits
    • 8.2.1. Crp Kits
    • 8.2.2. Hs-Crp Kits
  • 8.3. Software & Services
    • 8.3.1. Consulting Services
    • 8.3.2. Data Management Software

9. C-Reactive Protein Testing Market, by Technology

  • 9.1. Elisa
  • 9.2. Immunoturbidimetric
    • 9.2.1. Latex Enhanced
    • 9.2.2. Turbidimetric
  • 9.3. Nephelometry

10. C-Reactive Protein Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Clinics
    • 10.2.1. Tier I Clinics
    • 10.2.2. Tier II Clinics
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Hospital-Based Labs
    • 10.3.2. Independent Labs
  • 10.4. Hospitals
    • 10.4.1. General Hospitals
    • 10.4.2. Specialized Hospitals

11. C-Reactive Protein Testing Market, by Application

  • 11.1. Cancer
  • 11.2. Cardiovascular Diseases
    • 11.2.1. Coronary Heart Disease
    • 11.2.2. Stroke
  • 11.3. Diabetes
  • 11.4. Infection & Inflammatory Disorders
    • 11.4.1. Autoimmune Disorders
    • 11.4.2. Bacterial Infections
    • 11.4.3. Viral Infections

12. C-Reactive Protein Testing Market, by Test Type

  • 12.1. Quantitative
    • 12.1.1. Automated Tests
    • 12.1.2. Manual Tests
  • 12.2. Semi-Quantitative
    • 12.2.1. Immunophoresis Tests
    • 12.2.2. Lateral Flow Tests

13. C-Reactive Protein Testing Market, by Sample Type

  • 13.1. Plasma
    • 13.1.1. Edta Plasma
    • 13.1.2. Heparin Plasma
  • 13.2. Serum
  • 13.3. Whole Blood
    • 13.3.1. Capillary Blood
    • 13.3.2. Venous Blood

14. C-Reactive Protein Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. C-Reactive Protein Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. C-Reactive Protein Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Diagnostics International AG
    • 17.3.2. Abbott Laboratories, Inc.
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Danaher Corporation
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. bioMerieux SA
    • 17.3.7. Ortho Clinical Diagnostics, LLC
    • 17.3.8. DiaSorin S.p.A.
    • 17.3.9. Bio-Rad Laboratories, Inc.
    • 17.3.10. Randox Laboratories Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. C-REACTIVE PROTEIN TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. C-REACTIVE PROTEIN TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. C-REACTIVE PROTEIN TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SE